Observational Study of Osteoblast Activity in Velcade(Bortezomib) IV Treated Multiple Myeloma Patients.
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2014
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Pharmacodynamics
- Sponsors Janssen
- 10 Jun 2017 Biomarkers information updated
- 09 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Dec 2009 New trial record